Toulon Cedex 9

• A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l … Pending
  2024-512195-35-00 5 Stage I adenocarcinoma non-small cell lung cancer (NSCLC) with ctDNA-p
• PRODIGE 104 – NEOPREDICT A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients … Pending
  2024-519753-11-00 4 Resectable borderline pancreatic adenocarcinoma
• RIFAMAB : Rifabutin versus rifampicin, staphylococcal prosthetic joint infection, multicenter randomized, open-label, non-inferiority trial Pending
  2024-519894-20-01 5 Adult with an staphylococcal prosthetic joint infection treated with d
• MAINRITSys : Rituximab vs placebo for maintenance in systemic sclerosis – interstitial lung disease Pending
  2025-521331-36-00 10 Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%)
• A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythema … Pending
  2025-523670-17-00 5 Systemic lupus erythematosus
• Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting
  2025-521865-29-00 4 2026-04-30 moderate-to-severe hidradenitis suppurativa
• A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting
  2024-520337-80-00 5 2026-01-07 Palmoplantar Pustulosis
• ISASOCUT-IFM2022-05-Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib, lenalidomide and dexamethasone in the treatment of … Recruiting
  2024-517099-39-00 4 2024-11-18 Newly diagnosed transplant ineligible multiple myeloma
• A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III N … Recruiting
  2023-503920-14-00 5 2024-01-02 Non-Small Cell Lung Cancer (NSCLC)
• Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting
  2023-504670-38-00 4 2023-11-17 Extensive disease Small Cell Lung Cancer
• A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting
  2024-517337-41-00 5 2026-05-12 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutated NSCLC
• PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting
  2023-505046-26-00 5 2026-05-07 Colon carcinoma
• Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting
  2024-519208-29-00 4 2026-04-02 Pleural mesothelioma
• A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting
  2024-511362-37-00 5 2026-02-18 Non squamous non-small cell lung cancer (NSCLC)
• ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus triflurid … Recruiting
  2025-522395-92-00 5 2025-12-15 metastatic oeso-gastric adenocarcinoma
• A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting
  2024-516834-36-00 5 2025-07-08 Locally recurrent unresectable or metastatic TNBC with tumors expressi
• Safety, efficacy, and pharmacokinetics of BNT327 in combination with chemotherapy and other investigational agents for lung cancer Recruiting
  2024-515764-31-00 10 2025-06-13 Non-small cell lung cancer
• Intra-arterial thrombolysis after SUCCESSful reperfusion of acute ischemic stroke Recruiting
  2023-506935-14-01 5 2025-06-01 Ischemic stroke
• A clinical study of zilovertamab vedotin in people with large B-cell lymphoma (MK-2140-010) Recruiting
  2024-515566-13-00 5 2025-03-19 Diffuse Large B-Cell Lymphoma (DLBCL)
• A global phase III study to investigate the effectiveness and safety of rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-514281-39-00 5 2025-02-14 Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
• A global phase III study to investigate the effectiveness and safety of Rilvegostomig plus chemotherapy to that of pembrolizumab plus chemot … Recruiting
  2024-515008-38-00 5 2025-02-14 Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients with Operable No … Recruiting
  2023-509806-31-00 4 2025-02-11 Non-Small Cell Lung Cancer
• A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Can … Recruiting
  2023-509340-10-00 5 2024-10-29 Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
• Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting
  2023-508012-35-00 5 2024-10-02 Newly diagnosed NSCLC with resectable clinical Stage II, IIIA or IIIB

Showing 1–24 of 73 trials